154 related articles for article (PubMed ID: 37434119)
1. The PRO-RCC study: a long-term PROspective Renal Cell Carcinoma cohort in the Netherlands, providing an infrastructure for 'Trial within Cohorts' study designs.
Yildirim H; Widdershoven CV; Aarts MJ; Bex A; Bloemendal HJ; Bochove-Overgaauw DM; Hamberg P; Herbschleb KH; van der Hulle T; Lagerveld BW; van Oijen MG; Oosting SF; van Thienen JV; van der Veldt AA; Westgeest HM; Zeijdner EE; Aben KK; van den Hurk C; Zondervan PJ; Bins AD
BMC Cancer; 2023 Jul; 23(1):648. PubMed ID: 37434119
[TBL] [Abstract][Full Text] [Related]
2. Cohort profile - the Renal cell cancer: Lifestyle, prognosis and quality of life (ReLife) study in the Netherlands.
Maurits JSF; Sedelaar JPM; Aben KKH; Kampman E; ; Kiemeney LALM; Vrieling A
BMJ Open; 2023 Mar; 13(3):e066909. PubMed ID: 36972960
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
5. Better survival of renal cell carcinoma in patients with inflammatory bowel disease.
Derikx LA; Nissen LH; Drenth JP; van Herpen CM; Kievit W; Verhoeven RH; Mulders PF; Hulsbergen-van de Kaa CA; Boers-Sonderen MJ; van den Heuvel TR; Pierik M; Nagtegaal ID; Hoentjen F; ; ;
Oncotarget; 2015 Nov; 6(35):38336-47. PubMed ID: 26447542
[TBL] [Abstract][Full Text] [Related]
6. Electronic patient-reported outcome (e-PRO) monitoring for adverse event management during cabozantinib treatment in patients with advanced renal cell carcinoma: protocol for a three-arm, randomised, multicentre phase II trial (e-PRO vs paper-PRO or usual care).
Osawa T; Fujii Y; Kimura G; Kitamura H; Nagashima Y; Iizumi S; Osaka T; Tsubouchi R; Shinohara N
BMJ Open; 2023 Jul; 13(7):e070275. PubMed ID: 37495393
[TBL] [Abstract][Full Text] [Related]
7. How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting.
Breckenridge K; Bekker HL; Gibbons E; van der Veer SN; Abbott D; Briançon S; Cullen R; Garneata L; Jager KJ; Lønning K; Metcalfe W; Morton RL; Murtagh FE; Prutz K; Robertson S; Rychlik I; Schon S; Sharp L; Speyer E; Tentori F; Caskey FJ
Nephrol Dial Transplant; 2015 Oct; 30(10):1605-14. PubMed ID: 25982327
[TBL] [Abstract][Full Text] [Related]
8. Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research.
Burbach JP; Kurk SA; Coebergh van den Braak RR; Dik VK; May AM; Meijer GA; Punt CJ; Vink GR; Los M; Hoogerbrugge N; Huijgens PC; Ijzermans JN; Kuipers EJ; de Noo ME; Pennings JP; van der Velden AM; Verhoef C; Siersema PD; van Oijen MG; Verkooijen HM; Koopman M
Acta Oncol; 2016 Nov; 55(11):1273-1280. PubMed ID: 27560599
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
[TBL] [Abstract][Full Text] [Related]
11. Implementation of patient-reported outcome measures and patient-reported experience measures in melanoma clinical quality registries: a systematic review.
Blood Z; Tran A; Caleo L; Saw R; Dieng M; Shackleton M; Soyer HP; Arnold C; Mann GJ; Morton RL
BMJ Open; 2021 Feb; 11(2):e040751. PubMed ID: 33574144
[TBL] [Abstract][Full Text] [Related]
12. Body mass index as independent predictor of overall survival in patients with advanced renal cell carcinoma at start of systemic treatment-Analyses from the German clinical RCC-Registry.
Goebell PJ; Müller L; Hübner A; Harich HD; Boller E; Koska M; Jänicke M; Marschner N;
Urol Oncol; 2018 Oct; 36(10):470.e1-470.e9. PubMed ID: 30131294
[TBL] [Abstract][Full Text] [Related]
13. Use of patient-reported outcome measures and patient-reported experience measures in renal units in Australia and New Zealand: A cross-sectional survey study.
Morton RL; Lioufas N; Dansie K; Palmer SC; Jose MD; Raj R; Salmon A; Sypek M; Tong A; Ludlow M; Boudville N; McDonald S
Nephrology (Carlton); 2020 Jan; 25(1):14-21. PubMed ID: 30838732
[TBL] [Abstract][Full Text] [Related]
14. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study).
Schmidinger M; Bamias A; Procopio G; Hawkins R; Sanchez AR; Vázquez S; Srihari N; Kalofonos H; Bono P; Pisal CB; Hirschberg Y; Dezzani L; Ahmad Q; Jonasch E;
Oncologist; 2019 Apr; 24(4):491-497. PubMed ID: 30867244
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review.
Motzer RJ; Rane PP; Saretsky TL; Pawar D; Martin Nguyen A; Sundaram M; Burgents J; Pandey R; Rudell K
Eur Urol; 2023 Oct; 84(4):406-417. PubMed ID: 37550153
[TBL] [Abstract][Full Text] [Related]
16. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design.
Doppenberg D; Besselink MG; van Eijck CHJ; Intven MPW; Koerkamp BG; Kazemier G; van Laarhoven HWM; Meijerink M; Molenaar IQ; Nuyttens JJME; van Os R; van Santvoort HC; van Tienhoven G; Verkooijen HM; Versteijne E; Wilmink JW; Lagerwaard FJ; Bruynzeel AME;
BMC Cancer; 2022 Dec; 22(1):1363. PubMed ID: 36581914
[TBL] [Abstract][Full Text] [Related]
18. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
19. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
[TBL] [Abstract][Full Text] [Related]
20. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
